Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Kilickap, S.Demirci, U.Buğdaycı, F.Tural, D.Korkmaz, T.Paydas, S.Cicin, İrfanSeber, Selçuk2022-05-112022-05-1120191556-08641556-1380https://doi.org/10.1016/j.jtho.2019.08.1166https://hdl.handle.net/20.500.11776/8981[No Abstract Available]en10.1016/j.jtho.2019.08.1166info:eu-repo/semantics/openAccessALK positiveROS1 positiveLorlatinibAdvanced stage lung cancerLorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in TurkeyConference Object1410S558S559Q1WOS:000492162203082